<!doctype html><html class=no-js lang=en><head><meta charset=UTF-8><meta name=viewport content="width=device-width,initial-scale=1"><title>ç§‘ç ”æ—¥æŠ¥ 2025-11-27 - ç”Ÿä¿¡æ™®æ‹‰æ–¯</title>
<script>(function(e,t){e[t]=e[t].replace("no-js","js")})(document.documentElement,"className")</script><meta name=description content><meta property="og:url" content="https://ixxmu.github.io/posts/dailyreports/2025-11-27/"><meta property="og:site_name" content="ç”Ÿä¿¡æ™®æ‹‰æ–¯"><meta property="og:title" content="ç§‘ç ”æ—¥æŠ¥ 2025-11-27"><meta property="og:description" content="ğŸ“… Daily Report - 2025-11-27 ä»Šæ—¥ç­›é€‰å‡º 84 æ¡å†…å®¹ï¼Œæ¥è‡ª 4 ä¸ªæ¥æº"><meta property="og:locale" content="zh_cn"><meta property="og:type" content="article"><meta property="article:section" content="posts"><meta property="article:published_time" content="2025-11-27T00:00:00+00:00"><meta property="article:modified_time" content="2025-11-27T00:00:00+00:00"><meta property="article:tag" content="Research"><meta property="article:tag" content="Daily"><meta property="article:tag" content="Week482025"><meta itemprop=name content="ç§‘ç ”æ—¥æŠ¥ 2025-11-27"><meta itemprop=description content="ğŸ“… Daily Report - 2025-11-27 ä»Šæ—¥ç­›é€‰å‡º 84 æ¡å†…å®¹ï¼Œæ¥è‡ª 4 ä¸ªæ¥æº"><meta itemprop=datePublished content="2025-11-27T00:00:00+00:00"><meta itemprop=dateModified content="2025-11-27T00:00:00+00:00"><meta itemprop=wordCount content="2894"><meta itemprop=keywords content="Research,Daily,Week482025"><meta name=twitter:card content="summary"><meta name=twitter:title content="ç§‘ç ”æ—¥æŠ¥ 2025-11-27"><meta name=twitter:description content="ğŸ“… Daily Report - 2025-11-27 ä»Šæ—¥ç­›é€‰å‡º 84 æ¡å†…å®¹ï¼Œæ¥è‡ª 4 ä¸ªæ¥æº"><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link rel=dns-prefetch href=//fonts.googleapis.com><link rel=dns-prefetch href=//fonts.gstatic.com><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Open+Sans:400,400i,700"><link rel=stylesheet href=../../../css/style.css><link rel=stylesheet href=../../../css/custom.css><link rel="shortcut icon" href=../../../favicon.ico></head><body class=body><div class="container container--outer"><header class=header><div class="container header__container"><div class=logo><a class=logo__link href=../../../ title=ç”Ÿä¿¡æ™®æ‹‰æ–¯ rel=home><div class="logo__item logo__text"><div class=logo__title>ç”Ÿä¿¡æ™®æ‹‰æ–¯</div><div class=logo__tagline>è¿‘åå¹´æœ€å€¼å¾—ä¸Šæ‰‹çš„ç”Ÿç‰©åŒ»å­¦ç”Ÿä¿¡ä»£ç </div></div></a></div><nav class=menu><button class=menu__btn aria-haspopup=true aria-expanded=false tabindex=0>
<span class=menu__btn-title tabindex=-1>Menu</span></button><ul class=menu__list><li class=menu__item><a class=menu__link href=../../../posts/><span class=menu__text>æ–‡ç« </span></a></li><li class=menu__item><a class=menu__link href=../../../tags/><span class=menu__text>æ ‡ç­¾</span></a></li><li class=menu__item><a class=menu__link href=../../../about/><span class=menu__text>å…³äº</span></a></li></ul></nav></div></header><div class="wrapper flex"><div class=primary><main class=main role=main><article class=post><header class=post__header><meta name=referrer content="never"><h1 class=post__title>ç§‘ç ”æ—¥æŠ¥ 2025-11-27</h1><div class="post__meta meta"><div class="meta__item-datetime meta__item"><svg class="meta__icon icon icon-time" width="16" height="14" viewBox="0 0 30 28"><path d="M15 0a14 14 0 110 28 1 1 0 010-28m0 3a3 3 0 100 22 3 3 0 000-22m1 4h-2v8.4l6.8 4.4L22 18l-6-3.8z"/></svg><time class=meta__text datetime=2025-11-27T00:00:00Z>2025-11-27</time></div><div class="meta__item-categories meta__item"><svg class="meta__icon icon icon-category" width="16" height="16" viewBox="0 0 16 16"><path d="m7 2 1 2h8v11H0V2z"/></svg><span class=meta__text><a class=meta__link href=../../../categories/dailyreport/ rel=category>DailyReport</a></span></div><div class="meta__item-author meta__item"><svg class="meta__icon icon icon-author" width="16" height="16" viewBox="0 0 16 16"><path d="M8 1c2 0 3.5 2 3.5 4.5S10 9 10 9c3 1 4 2 4 6H2c0-4 1-5 4-6 0 0-1.5-1-1.5-3.5S6 1 8 1"/></svg><span class=meta__text>Bloger</span></div></div></header><div class="post__toc toc"><div class=toc__title>Page content</div><div class=toc__menu><nav id=TableOfContents><ul><li><a href=#-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</a><ul><li><a href=#-å…¬ä¼—å·>ğŸ“° å…¬ä¼—å·</a></li><li><a href=#-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</a></li><li><a href=#-æœŸåˆŠæ–‡ç« >ğŸ”¬ æœŸåˆŠæ–‡ç« </a></li><li><a href=#-åšå®¢æ›´æ–°>ğŸ§ª åšå®¢æ›´æ–°</a></li></ul></li><li><a href=#-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</a><ul><li></li></ul></li><li><a href=#-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</a></li><li><a href=#-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</a></li></ul></nav></div></div><div class="content post__content clearfix"><h1 id=-daily-report---2025-11-27>ğŸ“… Daily Report - 2025-11-27</h1><blockquote><p>ä»Šæ—¥ç­›é€‰å‡º <strong>84</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>4</strong> ä¸ªæ¥æº</p></blockquote><div class=powered-by-top>Powered by <a href=https://kyplus.de>ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href=https://claude.ai>Claude</a></div><hr><h2 id=-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2><h3 id=-å…¬ä¼—å·>ğŸ“° å…¬ä¼—å·</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
é¦–æ¬¡è¯å®è‚ ç™Œå¯åˆ©ç”¨ä¸Šçš®ç»†èƒå¯å¡‘æ€§å¯¹MAPKé€šè·¯æŠ‘åˆ¶å‰‚è€è¯ï¼›å“ˆä½›å›¢é˜Ÿæ„å»º170ä¸‡Tç»†èƒå›¾è°±ï¼Œä¸ºç”Ÿä¿¡æ³¨é‡Šæä¾›â€œé»„é‡‘æ ‡å°ºâ€ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>å¾®ç”Ÿç‰©ç»„ä¸å…ç–«äº’ä½œæœºåˆ¶æ¢ç´¢ï¼Œåˆ©ç”¨å•ç»†èƒä¸ç©ºé—´å¤šç»„å­¦ã€‚</li><li>è‚¿ç˜¤å¾®ç¯å¢ƒä¸å…ç–«æ²»ç–—ç–—æ•ˆæå‡ï¼Œèšç„¦ä¸­æ€§ç²’ç»†èƒäºšå‹ã€ä¸‰çº§æ·‹å·´ç»“æ„ï¼ˆTLSï¼‰åˆ†æã€‚</li><li>è‚¿ç˜¤è€è¯æœºåˆ¶è§£æï¼Œæ¶‰åŠCAF-ç™Œç»†èƒé€šè®¯ã€åŸºå› ç»„å€å¢ã€å·¨å™¬ç»†èƒçº¿ç²’ä½“åŠŸèƒ½é‡å¡‘ã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>å¤šç»„å­¦ï¼ˆå•ç»†èƒã€ç©ºè½¬ã€ä»£è°¢ç»„ã€ChIP-seqç­‰ï¼‰è”åˆåˆ†æï¼Œæå‡ç ”ç©¶æ·±åº¦ä¸å‘æ–‡æ½œåŠ›ã€‚</li><li>æ–°å‹è‚¿ç˜¤èŠ¯ç‰‡æŠ€æœ¯æ¨¡æ‹Ÿå®ä½“ç˜¤å¾®ç¯å¢ƒï¼ŒåŠ©åŠ›CAR-Tç–—æ³•ç ”å‘ã€‚</li></ul><h3 id=-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
EZH2ä¸TEADè”åˆé¶å‘æ²»ç–—Hippoé€šè·¯çªå˜ç™Œç—‡ï¼Œé€šè¿‡è‚¿ç˜¤å†…åœ¨çš„å…ˆå¤©å…ç–«ä¿¡å·è¯±å¯¼ç»†èƒå‡‹äº¡ï¼›åŒæ—¶ï¼ŒPRC2ä¸DNAç”²åŸºåŒ–ç›¸äº’ä½œç”¨ä»‹å¯¼ç¥ç»å†…åˆ†æ³Œå‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§ï¼Œä¸ºç™Œç—‡æ²»ç–—æä¾›æ–°ç­–ç•¥ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li><strong>ç™Œç—‡è¡¨è§‚é—ä¼ è°ƒæ§ä¸æ²»ç–—</strong>ï¼šèšç„¦EZH2ã€DNMTã€PRC2ç­‰è¡¨è§‚é—ä¼ è°ƒæ§å› å­åœ¨å‰åˆ—è…ºç™Œã€ä¹³è…ºç™Œç­‰ç™Œç—‡å‘ç”Ÿå‘å±•ä¸­çš„ä½œç”¨ï¼Œæ¢ç´¢è”åˆé¶å‘æ²»ç–—ç­–ç•¥ã€‚</li><li><strong>è‚¿ç˜¤å…ç–«ä¸ä¿¡å·é€šè·¯</strong>ï¼šç ”ç©¶Hippoé€šè·¯çªå˜ç™Œç—‡çš„å†…åœ¨å…ç–«ä¿¡å·ï¼Œä»¥åŠCAR-NKç»†èƒç–—æ³•å¯¹è‚¿ç˜¤å…ç–«çš„é‡å¡‘ä½œç”¨ã€‚</li><li><strong>ç»†èƒè°±ç³»å¯å¡‘æ€§æœºåˆ¶</strong>ï¼šè§£æDNAç”²åŸºåŒ–ä¸PRC2åœ¨ç¥ç»å†…åˆ†æ³Œå‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§ä¸­çš„è°ƒæ§æœºåˆ¶ã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li><strong>å¤šç»„å­¦æ•´åˆåˆ†æ</strong>ï¼šç»“åˆRNA-seqã€ChIP-seqã€ATAC-seqã€RRBSç­‰æŠ€æœ¯ï¼Œæ·±å…¥è§£æåŸºå› è¡¨è¾¾ã€æŸ“è‰²è´¨å¯åŠæ€§ã€DNAç”²åŸºåŒ–åŠè›‹ç™½è´¨ç»“åˆæ¨¡å¼ã€‚</li><li><strong>å•ç»†èƒç©ºé—´è½¬å½•ç»„å­¦</strong>ï¼šæ­ç¤ºåµå·¢è‚¿ç˜¤æµ¸æ¶¦æ€§NKç»†èƒçš„è°ƒæ§ç½‘ç»œï¼Œä»¥åŠèƒç›˜ç»„ç»‡åœ¨å…ˆå…†å­ç—«ä¸­çš„ç©ºé—´è½¬å½•ç»„å­¦ç‰¹å¾ã€‚</li></ul><h3 id=-æœŸåˆŠæ–‡ç« >ğŸ”¬ æœŸåˆŠæ–‡ç« </h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
Camrelizumabè”åˆrivoceranibä½œä¸ºä¸å¯åˆ‡é™¤è‚ç»†èƒç™Œçš„ä¸€çº¿æ²»ç–—ï¼Œåœ¨å›½é™…ä¸‰æœŸä¸´åºŠç ”ç©¶ï¼ˆCARES-310ï¼‰ä¸­æ˜¾ç¤ºå‡ºä¼˜äºsorafenibçš„æœ€ç»ˆç–—æ•ˆã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>è‚ç»†èƒç™Œä¸€çº¿æ²»ç–—ï¼šè¯„ä¼°Camrelizumabè”åˆrivoceranibä¸sorafenibçš„ç–—æ•ˆåŠå®‰å…¨æ€§ã€‚</li><li>IDHçªå˜èƒ¶è´¨ç˜¤ï¼šæ¢è®¨å¢åŠ ç¥ç»å¤–ç§‘åˆ‡é™¤èŒƒå›´å¯¹ä¸´åºŠå®è·µçš„è½¬åŒ–æ„ä¹‰ã€‚</li><li>ç™Œç—‡ç ”ç©¶ä¸ä¼ æ’­ï¼šå…³æ³¨ç™Œç—‡ç§‘å­¦ã€åˆ›æ–°ä»¥åŠç™Œç—‡ä¸å–œå‰§çš„è·¨ç•Œå¯¹è¯ã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>éšæœºã€å¼€æ”¾æ ‡ç­¾ã€å›½é™…ä¸‰æœŸä¸´åºŠç ”ç©¶è®¾è®¡ï¼Œä¸ºè‚ç™Œæ²»ç–—æä¾›é«˜çº§åˆ«è¯æ®ã€‚</li><li>ç¥ç»å¤–ç§‘æ‰‹æœ¯åˆ‡é™¤èŒƒå›´çš„é‡åŒ–ä¸ä¸´åºŠè½¬åŒ–ç ”ç©¶ã€‚</li></ul><h3 id=-åšå®¢æ›´æ–°>ğŸ§ª åšå®¢æ›´æ–°</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
2026å¹´ä¼¦æ•¦åŸºå› ç»„ä¸ç”Ÿç‰©æ•°æ®èŠ‚å°†æ±‡èšæœ€å‰æ²¿çš„ç§‘å­¦ã€æŠ€æœ¯ä¸äººè„‰ï¼Œèšç„¦åŸºå› ç»„å­¦å’Œç”Ÿç‰©æ•°æ®é¢†åŸŸçš„æœ€æ–°è¿›å±•ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>åŸºå› ç»„å­¦ç ”ç©¶</li><li>ç”Ÿç‰©æ•°æ®åˆ†æ</li><li>ä¸´åºŠåº”ç”¨åˆ›æ–°</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>è·¨é¢†åŸŸäº¤æµä¸åˆä½œå¹³å°</li><li>æ¢ç´¢å‰æ²¿ç§‘å­¦æŠ€æœ¯</li></ul><hr><h2 id=-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</h2><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ“° å…¬ä¼—å· (35æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å‰10æ¡>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4><p><strong>1.</strong> â­ <strong>æœ€æ–°10+ç”Ÿä¿¡ï¼Œç©ºè½¬+å•ç»†èƒ+H3K18la ChIP-seq+CRISPR+bulkè½¬å½•ç»„ï¼Œå¤šç»„å­¦ç»å…¸å¥½æ–‡ï¼Œå€¼å¾—æ”¶è—ï¼</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šChIP-seqã€å•ç»†èƒã€è½¬å½•ç»„ã€ç”Ÿä¿¡</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504068&amp;idx=1&amp;sn=2e2f6cbfe2347550929544b689de7688">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> â­ <strong>ã€å‚ä¼šæé†’ã€‘åˆ©ç”¨å•ç»†èƒä¸ç©ºé—´å¤šç»„å­¦æ¢ç´¢å¾®ç”Ÿç‰©ç»„ä¸å…ç–«äº’ä½œæœºåˆ¶</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼š10x Genomics</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€å¾®ç”Ÿç‰©ã€å•ç»†èƒã€ç©ºé—´ç»„å­¦</li><li>ğŸ“ <strong>æè¿°</strong>ï¼š11æœˆ26æ—¥ç›´æ’­ï¼Œä¸ä¸“å®¶å…±åŒæ­ç§˜ â€œå¦‚ä½•åˆ©ç”¨å•ç»†èƒä¸ç©ºé—´å¤šç»„å­¦æ¢ç´¢å¾®ç”Ÿç‰©ç»„ä¸å…ç–«äº’ä½œæœºåˆ¶â€ã€‚</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzU1MDk1NTY5MA==&amp;mid=2247541027&amp;idx=1&amp;sn=93e53ed520d8a7f10329f874489964ea">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> â­ <strong>æœ€æ–°10åˆ†ç”Ÿä¿¡ï¼Œå•ç»†èƒ+ç©ºè½¬å¤šç»„å­¦è¿›è¡Œä¸­æ€§ç²’ç»†èƒäºšå‹åˆ†æï¼Œè¯†åˆ« CTCF+TANï¼Œé¶å‘CTCFæ”¹å–„å…ç–«æ²»ç–—ç–—æ•ˆï¼</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€å•ç»†èƒã€ç”Ÿä¿¡</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504068&amp;idx=5&amp;sn=17676606db045d7b6bcabfd7a0488d4e">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>4.</strong> â­ <strong>10æœˆæœ€æ–°26+ç”Ÿä¿¡ï¼Œå¤šç»„å­¦ç©ºé—´å…ç–«è°±åˆ†æç¡®å®šäº†ä¸‰çº§æ·‹å·´ç»“æ„ï¼ˆTLSï¼‰çš„äºšç¾¤å¹¶è¿›è¡Œæ·±å…¥åˆ†æï¼Œå»ºè®®æ”¶è—ï¼</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€æ·‹å·´ã€ç”Ÿä¿¡</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504068&amp;idx=3&amp;sn=b7ff58629c7d764112a4c1721968915e">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>5.</strong> â­ <strong>æœ€æ–°8+ç”Ÿä¿¡ï¼Œå¤šç»„å­¦è¯†åˆ«ä¸‰çº§æ·‹å·´ç»“æ„ï¼ˆTLSï¼‰ç»“æ„å¹¶è¿›è¡Œé’ˆå¯¹æ€§åˆ†æã€‚é¢„æµ‹é¢„ååŠå…ç–«æ²»ç–—ç–—æ•ˆï¼Œå€¼å¾—å€Ÿé‰´ï¼</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€æ·‹å·´ã€ç”Ÿä¿¡</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504068&amp;idx=2&amp;sn=79cb771915f774099f30eae6af65c829">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>6.</strong> â­ <strong>å•ç»†èƒ+ç©ºè½¬+ä»£è°¢ç»„ï¼Œå…¬å¼€æ•°æ®é›†æ‰¾å‡ºäº®ç‚¹å°±èƒ½å‘1åŒº12åˆ†</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡äºº</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šä»£è°¢ã€ä»£è°¢ç»„ã€å•ç»†èƒ</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248818&amp;idx=8&amp;sn=11df37e0b4894d272c6da864a67d8573">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>7.</strong> â­ <strong>Cancer Cellé‡ç£…ï¼šè‚¿ç˜¤ç«Ÿè¢«è‡ªå·±äººèƒŒåˆºï¼çªå˜å¼•çˆ†å…ç–«æ²»ç–—</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡äºº</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€cancerã€å…ç–«</li><li>ğŸ“ <strong>æè¿°</strong>ï¼š10æœˆ16æ—¥ï¼ŒCancer Cellå‘è¡¨äº†å¾·å·å¤§å­¦MDå®‰å¾·æ£®ç™Œç—‡ä¸­å¿ƒPadmanee Sharmaæ•™æˆå›¢é˜Ÿçš„é‡</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248818&amp;idx=3&amp;sn=2a28fd3db9ace259564e4294c2ea7a1c">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>8.</strong> â­ <strong>çœ‹çœ‹NCç”Ÿä¿¡ä¸ºä¸»çš„æ–‡ç« éœ€è¦å¤šå°‘å·¥ä½œé‡ï¼Œå•ç»†èƒå¤šç»„å­¦åˆ†æå­¦ä¹ ã€‚å‘ç° IDH1 æŠ‘åˆ¶å‰‚å¯é€†è½¬é«“æ¯ç»†èƒç˜¤æ”¾ç–—è€è¯</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡é’±åŒå­¦</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè€è¯ã€å•ç»†èƒã€ç”Ÿä¿¡</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šç”Ÿä¿¡æ–‡ç« å­¦ä¹ </li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&amp;mid=2247495727&amp;idx=1&amp;sn=a703f13586da1d4d7fa702a45cb0560e">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>9.</strong> <strong>pH/ROSå“åº”å¾®é’ˆé‡å¡‘å·¨å™¬ç»†èƒçº¿ç²’ä½“åŠŸèƒ½</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šåŒåŒ»æµäº‘Medfocus</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå·¨å™¬ç»†èƒã€çº¿ç²’ä½“</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šâ€œä»£è°¢å…ç–«é‡ç¼–ç¨‹â€ç­–ç•¥ï¼Œé€šè¿‡çº§è”é¶å‘å¾®é’ˆç²¾å‡†è°ƒæ§å·¨å™¬ç»†èƒçº¿ç²’ä½“ä»£è°¢ï¼Œå®ç°äº†ç³–å°¿ç—…åˆ›é¢çš„æ— ç˜¢ç—•æ„ˆåˆã€‚</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzk3NTY2NDk1Nw==&amp;mid=2247488308&amp;idx=1&amp;sn=3e4910c028314a53cc716f48ad36d63b">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>10.</strong> <strong>æ‰¬å·å¤§å­¦å›¢é˜Ÿèšç„¦â€œè‚ è„‘è½´â€ç²¾å‡†ä¸Šåˆ†ï¼è¿™å¥—èŒç¾¤å˜åŒ–-ä»£è°¢ç‰©æ”¹å˜-é€šè·¯è°ƒæ§çš„æ€è·¯ï¼Œå€¼å¾—æ¨æ•²ï¼</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç¥ç»å²›</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šä»£è°¢ã€é€šè·¯</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzkyNzcxMjEyMg==&amp;mid=2247498015&amp;idx=1&amp;sn=9c1867076da46b8508ff9cea504d36c5">æŸ¥çœ‹åŸæ–‡</a></li></ul><blockquote><p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 25 æ¡å†…å®¹ï¼Œè¯¦è§ <a href=#%E6%9B%B4%E5%A4%9A-%E5%85%AC%E4%BC%97%E5%8F%B7>æ–‡æœ«</a></p></blockquote></div></details><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ§¬ æ•°æ®å‰æ²¿ (44æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å‰10æ¡-1>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4><p><strong>1.</strong> â­ <strong>GSE301957 å…±é¶å‘ EZH2 å’Œ TEAD é€šè¿‡ Hippo é€šè·¯çªå˜ç™Œç—‡ä¸­çš„è‚¿ç˜¤å›ºæœ‰å…ç–«ä¿¡å·é€šè·¯è¯±å¯¼ç»†èƒå‡‹äº¡ - æ¥è‡ª EZH2 åŸºå› ç ´åçš„ RNA-seq æ•°æ®</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immuneã€RNA-seqã€pathway</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Antja-Voy Hartley ; Zhaorong Li ; Matthew Booker ; Nicholas Tourtillot ; Pasi A JÃ¤nneSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTEA/TEF-domain [TEAD] inhibitors are being evaluated in clinical trials for cancers with alterations in the Hippo pathway including mesothelioma. We recently developed and showcased the potency of TEAD palmitoylation inhibitors MYF-03-69 and MYF-03-176 in mesothelioma cell lines. However, TEAD inhibition results in cell cycle arrest in cell line models with Hippo pathway alterations without inducing cell death, potentially limiting their long-term clinical efficacy. Using a genome-wide CRISPR/Cas9 screen, we identified EZH2 as a critical modulator of the cellular response to TEAD inhibition. Compared to single agent treatments, EZH2i/TEADi robustly triggered apoptosis and suppressed the growth of Hippo-mutated cells in vitro and in vivo. Mechanistically, EZH2i/TEADi-treated cells exhibited heightened activation of tumor-intrinsic innate immune signaling which resulted in DNA damage and subsequent apoptosis. Taken together, we propose this novel combinatorial strategy as a potential approach to enhancing the anti-tumor efficacy of single agent TEAD targeting therapies in Hippo pathway altered tumors. This GEO accession includes the data series associated with RNA-seq derived from pharmacologic disruption of EZH2.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301957">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> â­ <strong>GSE289248 å¤šæ¢³æŠ‘åˆ¶å¤åˆç‰© 2 ä¸ DNA ç”²åŸºåŒ–ä¹‹é—´çš„ä¸²æ‰°ä»‹å¯¼ç¥ç»å†…åˆ†æ³Œå‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§ [RNA-Seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seqã€methylation</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Richa Singh ; David S RickmanSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusAcquired changes in DNA methylation have been proposed as a mechanism underlying epigenetic plasticity in several cancer types. In prostate cancer, methylation changes are dynamic, with preclinical studies pointing to a tumor suppressor role of the DNA methyltransferase DNMT1 in early stage, in contrast to an oncogenic function of DNMT1 in later stage. The importance of DNA methylation dynamics during normal development and cell lineage fate decisions also points to DNA methylation having a critical function in lineage plasticity, yet the mechanisms by which DNA methylation changes drives lineage transitions in prostate cancer is not well understood. DNA methylation can directly repress gene expression but also cooperate with other epigenetic pathways to modulate downstream transcriptional activity. The enhancer of zeste homolog 2 (EZH2) protein is a subunit of the polycomb repressive complex 2 (PRC2) and catalyzer of the repressive histone 3 lysine 27 tri-methylation (H3K27me3) mark that also acts to suppress downstream transcriptional activity and has also been implicated in lineage plasticity. EZH2 is overexpressed in castration-resistant prostate cancer (CRPC) including NEPC and is an emerging therapeutic target. Although, the compensatory relationship between DNA methylation and EZH2 has been shown in embryonic stem cell studies and in some cancer types during acquired treatment resistance or immune evasion, how DNA methylation and EZH2/PRC2 interact to modulate prostate cancer lineage plasticity has not been characterized. In this study, we address the potential crosstalk between epigenetic pathways in advanced prostate cancer and demonstrate how DNA methylation and H3K27me3 profiles overlap and cooperate to reprogram the epigenome during prostate cancer lineage plasticity. Using both mouse and patient-derived models, we highlight the compensatory roles of these two repressive machineries during progression of CRPC towards a NE-lineage state. We predict their specific impact on NEPC progression by assessing the associated molecular alterations following genetic and pharmacological perturbations of each.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289248">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> â­ <strong>GSE289247 å¤šæ¢³æŠ‘åˆ¶å¤åˆç‰© 2 ä¸ DNA ç”²åŸºåŒ–ä¹‹é—´çš„ä¸²æ‰°ä»‹å¯¼ç¥ç»å†…åˆ†æ³Œå‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§ [ChIP-Seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€ChIP-seqã€methylation</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Richa Singh ; David S RickmanSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiens ; Mus musculusAcquired changes in DNA methylation have been proposed as a mechanism underlying epigenetic plasticity in several cancer types. In prostate cancer, methylation changes are dynamic, with preclinical studies pointing to a tumor suppressor role of the DNA methyltransferase DNMT1 in early stage, in contrast to an oncogenic function of DNMT1 in later stage. The importance of DNA methylation dynamics during normal development and cell lineage fate decisions also points to DNA methylation having a critical function in lineage plasticity, yet the mechanisms by which DNA methylation changes drives lineage transitions in prostate cancer is not well understood. DNA methylation can directly repress gene expression but also cooperate with other epigenetic pathways to modulate downstream transcriptional activity. The enhancer of zeste homolog 2 (EZH2) protein is a subunit of the polycomb repressive complex 2 (PRC2) and catalyzer of the repressive histone 3 lysine 27 tri-methylation (H3K27me3) mark that also acts to suppress downstream transcriptional activity and has also been implicated in lineage plasticity. EZH2 is overexpressed in castration-resistant prostate cancer (CRPC) including NEPC and is an emerging therapeutic target. Although, the compensatory relationship between DNA methylation and EZH2 has been shown in embryonic stem cell studies and in some cancer types during acquired treatment resistance or immune evasion, how DNA methylation and EZH2/PRC2 interact to modulate prostate cancer lineage plasticity has not been characterized. In this study, we address the potential crosstalk between epigenetic pathways in advanced prostate cancer and demonstrate how DNA methylation and H3K27me3 profiles overlap and cooperate to reprogram the epigenome during prostate cancer lineage plasticity. Using both mouse and patient-derived models, we highlight the compensatory roles of these two repressive machineries during progression of CRPC towards a NE-lineage state. We predict their specific impact on NEPC progression by assessing the associated molecular alterations following genetic and pharmacological perturbations of each.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289247">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>4.</strong> â­ <strong>GSE286958 å‰åˆ—è…ºè…ºç™Œå’Œç¥ç»å†…åˆ†æ³Œå‰åˆ—è…ºç™Œæ¨¡å‹çš„è¡¨è§‚é—ä¼ å­¦åˆ†æï¼Œä»¥äº†è§£DNMT-EZH2çš„ç›¸äº’ä½œç”¨ã€‚[RNA-Seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seqã€epigenetic</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Venkadakrishnan Varadha Balaji ; Beltran HimishaSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensEZH2-DNMT crosstalk is diverse across prostate adenocarcinoma and neuroendocrine prostate cancer.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286958">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>5.</strong> â­ <strong>GSE310915 æŸ“è‰²è´¨å¯åŠæ€§å’Œè½¬å½•ç»„å­¦çš„å•ç»†èƒæ•´åˆæ­ç¤ºåµå·¢è‚¿ç˜¤æµ¸æ¶¦é€‚åº”æ€§NKç»†èƒçš„è°ƒæ§ç½‘ç»œ</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€single-cellã€transcriptomics</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Yizhe Sun ; Meng Wan ; Solrun Kolbeinsdottir ; Kang Wang ; Shruti Khare ; Okan Gultekin ; Sahar Salehi ; Kaisa Lehti ; Ramanuj Dasgupta ; Theodoros Foukakis ; Martin Enge ; Dhifaf SarhanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensNatural killer (NK) cells are traditionally recognized for their rapid, non-specific responses against virus-infected or malignantly transformed cells, functioning as key effectors of innate immunity. However, a distinct subset known as adaptive NK (aNK) cells has been shown to acquire memory-like properties following viral infections, indicating their capacity for antigen-specific immune recall. Intriguingly, aNK cells have also been identified within the tumor microenvironment, where they can mediate tumor-specific recall responses. Yet, the regulatory mechanisms managing their function in tumor-infiltrating aNK cells remain largely unknown. In this study, we integrated publicly available multiomics datasets from ovarian cancer, including single-cell chromatin accessibility (scATAC-seq) and single-cell RNA sequencing (scRNA-seq), to identify chromatin-accessible regions and construct transcription factors (TF)-gene regulatory networks. To validate and extend these findings, we performed Smart-seq3 on NK cells isolated from ovarian tumors and applied SCENIC analysis to identify TF-driven gene regulation. By integrating results from both analyses, we identified PRDM1 and STAT2 as key TFs, along with their downstream targets CRCP and MTFP1, specifically enriched in tumor-infiltrating aNK cells. The expression levels of CRCP and MTFP1 positively correlated with NK cell infiltration in ovarian cancer tissues, suggesting their potential functions in supporting tumor-specific NK cell memory responses. In addition, external validation using data from the PROMIX clinical trial demonstrated that PRDM1 and STAT2 expression levels are positively associated with both overall survival and aNK cell-associated transcriptional features.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310915">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>6.</strong> â­ <strong>GSE293929 IPSCè¡ç”Ÿçš„CAR-NKç»†èƒå¤–å›Šæ³¡é‡å¡‘å·¨å™¬ç»†èƒå…ç–«å¹¶å¢å¼ºè‚¿ç˜¤æ¸…é™¤</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€macrophage</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Hao Zhang ; Peng Xia ; Bin Jin ; Minghe Zhang ; Jie LiuSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusChimeric antigen receptor (CAR) cell therapy has revolutionized the treatment of hematological malignancies; however, its efficacy in solid tumors remains limited due to dense stromal barriers and the immunosuppressive tumor microenvironment (TME), which hinder immune cell infiltration and persistence. To overcome these challenges, we propose an innovative strategy utilizing induced pluripotent stem cell (iPSC)-derived CAR-NK extracellular vesicles (CAR-iNEV), engineered from iPSC-differentiated NK cells. Unlike conventional CAR-NK cell therapies that rely on immortalized NK92 cell lines, our approach leverages iPSC-derived NK cells, reducing tumorigenic risk and enhancing CAR transduction efficiency. Additionally, we incorporate nanobody-based CAR constructs in place of traditional single-chain variable fragments (scFv), significantly improving CAR stability and expression efficiency. Beyond direct cytotoxicity, CAR-iNEV offers superior therapeutic advantages, including reduced systemic toxicity and enhanced drug delivery capabilities compared to CAR-iNK cells. In vivo studies demonstrate that CAR-iNEV exhibits exceptional safety and potent antitumor activity across multiple solid tumor xenograft and patient-derived xenograft (PDX) models in humanized mice. Mechanistically, CAR-iNEV not only directly eliminates tumor cells but also reprograms the TME by activating macrophage-derived nitric oxide synthase (NOS2), amplifying host antitumor immunity. These findings establish CAR-iNEV as a promising platform for solid tumor immunotherapy, particularly in relapsed and metastatic settings, providing a novel and effective strategy that bridges direct tumor targeting with immune microenvironment remodeling. This study lays the foundation for future clinical translation, advancing the next generation of cell-free CAR-based immunotherapies.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293929">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>7.</strong> â­ <strong>GSE221608 CRCæ‚£è€…æ­£å¸¸è‚ é»è†œç»„ç»‡ã€é…å¯¹çš„åŸå‘æ€§CRCç»„ç»‡å’Œè‚è½¬ç§»ç—…ç¶çš„è½¬å½•ç»„æµ‹åº</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€transcriptomeã€regex:intestin(e|al)</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Wen Ni ; Su Yao ; Jianming LiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTo investigate the key regulators in CRC progression, we carried out transcriptome sequencing in normal intestinal mucosal tissues, paired primary CRC tissues and liver metastases lesions in participants of CRC.We then performed gene expression profiling analysis using data obtained from RNA-seq of tissues.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE221608">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>8.</strong> <strong>GSE311014 ç»†èƒå› å­é©±åŠ¨çš„ç³–é˜è„‚ä»£è°¢è°ƒèŠ‚åŸä»£äººè‚¾å°çƒç³»è†œç»†èƒå†…è´¨ç½‘é’™ç¨³æ€</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcytokineã€metabolism</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Mariia Stefanenko ; Tessa M Ortiz ; Sandra G Mungaray ; Mykhailo Fedoriuk ; Oleg Palygin ; Stefano Berto ; Drew Moore ; Tamara K NowlingSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensGlycosphingolipids (GSLs), including hexosylceramides (HexCers), lactosylceramides (LacCers), and gangliosides composed of one or more sugar residues attached to ceramide, are essential components of cell membranes. Dysregulated GSL metabolism has been implicated in various inflammatory and autoimmune diseases, including lupus nephritis; however, its contribution to renal cell dysfunction remains largely unexplored. In this study, we demonstrate that in primary human renal mesangial cells (hRMCs), proinflammatory cytokines relevant to lupus elicit significant upregulation and secretion of inflammatory mediators that parallel intracellular and extracellular accumulation of HexCers and elevated cytosolic calcium (Ca2+) levels. The increase in cytosolic Ca2+ was attributed to a decrease in endoplasmic reticulum (ER) Ca2+ store capacity. Pharmacological inhibition of GSL synthesis with eliglustat significantly reduced HexCers levels and restored ER Ca2+ stores, but did not impact cytokine-induced cytokine/chemokine secretion or cell viability/proliferation. Together, these data suggest that elevated GSL synthesis modulates cytokine-induced ER CaÂ²âº dysregulation in mesangial cells and may play a role in the pathogenesis of lupus nephritis.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311014">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>9.</strong> <strong>GSE295902 EBF1 å’Œ PAX5 å¯¹ T ç»†èƒè°±ç³»æ½œèƒ½å‘æŒ¥å‰‚é‡ä¾èµ–æ€§çš„è¡¨è§‚é—ä¼ æŠ‘åˆ¶ä½œç”¨ [ATAC-seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šATAC-seqã€epigenetic</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Johanna Tingvall-Gustafsson ; Kim Hellerstedt ; Jonas UngerbÃ¤ck ; Mikael SigvardssonSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusB-lymphocyte development is dependent on the coordinated action of transcription factors controlling the expression of stage and lineage specific genes. To better understand gene regulation and changes in the epigenetic landscape in early B-cell development, we conducted combined SC-RNA/ATAC seq analysis of bone marrow progenitor populations, allowing us to build a developmental trajectory based on changes in epigenetic accessibility. This analysis identified a rapid shift in DNA accessibility, where T-lineage primed progenitors gained the epigenetic landscape of B-lymphocytes. The epigenetic switch correlated well with initiation of EBF1 and PAX5 transcription as well as their functional activity. As ectopic expression of EBF1 in Pax5-/- pro-B cells was not sufficient to mediate either the full activation of the B-lineage program of silencing of T-lineage associated genes, we conclude that PAX5 and EBF1 are independently essential for the establishment of the epigenetic landscape in normal B-cell development. This idea was supported by the finding that pro-B cells from mice with combined heterozygote deletion of the Ebf1 and Pax5 genes, carried a non-differentiated epigenetic landscape and expressed T-lineage associated genes. The importance of epigenetic silencing for the preservation of B-cell fate was supported by the finding that inhibition of the histone methylases EZH1 and EZH2 in pro-B cells, allowed for the activation of T-lineage genes and generation of T-lineage cells in response to Notch signaling. Hence, B-lymphoid commitment is associated with a transcription factor dose dependent epigenetic switch, silencing an inherent T-lineage potential in early lymphoid progenitors.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295902">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>10.</strong> <strong>GSE295900 EBF1 å’Œ PAX5 å¯¹ T ç»†èƒè°±ç³»æ½œèƒ½å‘æŒ¥å‰‚é‡ä¾èµ–æ€§çš„è¡¨è§‚é—ä¼ æŠ‘åˆ¶ä½œç”¨ [RNA-seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seqã€epigenetic</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Johanna Tingvall-Gustafsson ; Kim Hellerstedt ; Jonas UngerbÃ¤ck ; Mikael SigvardssonSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusB-lymphocyte development is dependent on the coordinated action of transcription factors controlling the expression of stage and lineage specific genes. To better understand gene regulation and changes in the epigenetic landscape in early B-cell development, we conducted combined SC-RNA/ATAC seq analysis of bone marrow progenitor populations, allowing us to build a developmental trajectory based on changes in epigenetic accessibility. This analysis identified a rapid shift in DNA accessibility, where T-lineage primed progenitors gained the epigenetic landscape of B-lymphocytes. The epigenetic switch correlated well with initiation of EBF1 and PAX5 transcription as well as their functional activity. As ectopic expression of EBF1 in Pax5-/- pro-B cells was not sufficient to mediate either the full activation of the B-lineage program of silencing of T-lineage associated genes, we conclude that PAX5 and EBF1 are independently essential for the establishment of the epigenetic landscape in normal B-cell development. This idea was supported by the finding that pro-B cells from mice with combined heterozygote deletion of the Ebf1 and Pax5 genes, carried a non-differentiated epigenetic landscape and expressed T-lineage associated genes. The importance of epigenetic silencing for the preservation of B-cell fate was supported by the finding that inhibition of the histone methylases EZH1 and EZH2 in pro-B cells, allowed for the activation of T-lineage genes and generation of T-lineage cells in response to Notch signaling. Hence, B-lymphoid commitment is associated with a transcription factor dose dependent epigenetic switch, silencing an inherent T-lineage potential in early lymphoid progenitors.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295900">æŸ¥çœ‹åŸæ–‡</a></li></ul><blockquote><p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 34 æ¡å†…å®¹ï¼Œè¯¦è§ <a href=#%E6%9B%B4%E5%A4%9A-%E6%95%B0%E6%8D%AE%E5%89%8D%E6%B2%BF>æ–‡æœ«</a></p></blockquote></div></details><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ”¬ æœŸåˆŠæ–‡ç«  (4æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å…¨éƒ¨4æ¡>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨4æ¡ï¼‰</h4><p><strong>1.</strong> <strong>Camrelizumab åŠ  rivoceranib ä¸ sorafenib ä½œä¸ºä¸å¯åˆ‡é™¤è‚ç»†èƒç™Œï¼ˆCARES-310ï¼‰çš„ä¸€çº¿æ²»ç–—ï¼šä¸€é¡¹éšæœºã€å¼€æ”¾æ ‡ç­¾ã€å›½é™…ä¸‰æœŸä¸´åºŠç ”ç©¶çš„æœ€ç»ˆåˆ†æ</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šBç»†èƒ</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext:</li><li>ğŸ”— <a href=https://m.x-mol.com/paper/1993375579267772416/t>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> <strong>ç™Œç—‡é©å‘½ï¼šç§‘å­¦ã€åˆ›æ–°ä¸å¸Œæœ›</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext:</li><li>ğŸ”— <a href=https://m.x-mol.com/paper/1993378347768459264/t>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> <strong>ç™Œç—‡ä¸å–œå‰§ï¼šä¸‰åœºå•å£å–œå‰§ç‰¹åˆ«èŠ‚ç›®å›é¡¾</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext:</li><li>ğŸ”— <a href=https://m.x-mol.com/paper/1993381112259391488/t>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>4.</strong> <strong>IDH çªå˜èƒ¶è´¨ç˜¤ç¥ç»å¤–ç§‘åˆ‡é™¤èŒƒå›´å¢åŠ ï¼šè½¬åŒ–ä¸ºæ ‡å‡†å®è·µçš„é—®é¢˜</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç¥ç»</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext:</li><li>ğŸ”— <a href=https://m.x-mol.com/paper/1993364037818232832/t>æŸ¥çœ‹åŸæ–‡</a></li></ul></div></details><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ§ª åšå®¢æ›´æ–° (1æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å…¨éƒ¨1æ¡>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰</h4><p><strong>1.</strong> <strong>ä¼¦æ•¦åŸºå› ç»„å­¦ä¸ç”Ÿç‰©æ•°æ®èŠ‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šgenomics</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šThe Festival of Genomics and Biodata 2026 offers two days of cutting edge science, technology and networking, bringing together researchers, clinicians and innovators across more than sixteen content theatres&mldr;</li><li>ğŸ”— <a href=https://www.rna-seqblog.com/the-festival-of-genomics-biodata-in-london/>æŸ¥çœ‹åŸæ–‡</a></li></ul></div></details><h2 id=-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2><table><thead><tr><th>å…³é”®è¯</th><th>å‡ºç°æ¬¡æ•°</th></tr></thead><tbody><tr><td>cancer</td><td>12</td></tr><tr><td>RNA-seq</td><td>10</td></tr><tr><td>ç”Ÿä¿¡</td><td>8</td></tr><tr><td>å…ç–«</td><td>7</td></tr><tr><td>epigenetic</td><td>7</td></tr><tr><td>transcriptome</td><td>7</td></tr><tr><td>å•ç»†èƒ</td><td>6</td></tr><tr><td>Tç»†èƒ</td><td>5</td></tr><tr><td>methylation</td><td>4</td></tr><tr><td>æ·‹å·´</td><td>3</td></tr><tr><td>é€šè·¯</td><td>3</td></tr><tr><td>è€è¯</td><td>3</td></tr><tr><td>tumor</td><td>3</td></tr><tr><td>è‚¿ç˜¤</td><td>3</td></tr><tr><td>leukemia</td><td>3</td></tr><tr><td>çº¿ç²’ä½“</td><td>2</td></tr><tr><td>ä»£è°¢</td><td>2</td></tr><tr><td>ChIP-seq</td><td>2</td></tr><tr><td>metabolism</td><td>2</td></tr><tr><td>Bç»†èƒ</td><td>2</td></tr></tbody></table><hr><h2 id=-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</h2><details><summary><a name=æ›´å¤š-å…¬ä¼—å·></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (25æ¡)</summary><div class=details-content markdown=1><ul><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504068&amp;idx=4&amp;sn=2eb56be1c84c35980ed88772fe507ddd">æœ€æ–°8åˆ†ç”Ÿä¿¡ï¼Œç©ºè½¬å¤šç»„å­¦åˆ†ææ­ç¤ºCAF-ç™Œç»†èƒé€šè®¯ä»‹å¯¼ PARPi è€è¯çš„å…¨æ–°æœºåˆ¶ï¼Œå†…å®¹å¾ˆå°‘ï¼Œä¼˜åŠ¿åœ¨äºè‡ªæµ‹æ•°æ®ï¼</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzI4ODc5MDI5NA==&amp;mid=2247503578&amp;idx=1&amp;sn=75967d869354773ae42eda1c0cfe122f">ã€Šè‡ªç„¶ã€‹ï¼šè‚ ç™Œé â€œå˜èº«â€é€ƒç”Ÿï¼ç§‘å­¦å®¶é¦–æ¬¡è¯å®ï¼Œè‚ ç™Œå¯åˆ©ç”¨ä¸Šçš®ç»†èƒå¯å¡‘æ€§å¯¹MAPKé€šè·¯æŠ‘åˆ¶å‰‚è€è¯</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzAxMDkxODM1Ng==&amp;mid=2247547209&amp;idx=1&amp;sn=0daa49c33e9aa7f357c4c9bd5c281039">pythonå•ç»†èƒå­¦ä¹ ï¼ˆä¸‰ï¼‰ï¼šbatch2æ•°æ®è¯»å–ä¸å¤„ç†</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507637&amp;idx=3&amp;sn=a905d162ab36a0f644bb784dc1a8cb33">Nature Genetics | ç»ˆç»“å˜å¼‚è‡´ç—…æ€§è¯„åˆ†â€œé€šèƒ€â€ï¼é¦–ä¸ªå…¨è›‹ç™½è´¨ç»„æ ¡å‡†æ¨¡å‹popEVEé‡å¡‘è‡´ç—…æ€§é¢„æµ‹æ ‡å‡†</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248818&amp;idx=5&amp;sn=b64f36971667d64dbb34427033cc3f21">é¡¶åˆŠé‡Œç¨‹ç¢‘çªç ´ï¼å“ˆä½›å›¢é˜Ÿç»˜ 170 ä¸‡ T ç»†èƒå›¾è°±ï¼Œç”Ÿä¿¡æ³¨é‡Šæœ‰äº† â€œé»„é‡‘æ ‡å°ºâ€</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656510953&amp;idx=4&amp;sn=cd1def5c8c6e8814e6d77c9989dd1ec6">æ–°è§’è‰²ï¼é‡åº†å¤§å­¦é™„å±è‚¿ç˜¤åŒ»é™¢å‘æ–‡ï¼šICIså…ç–«æ²»ç–—çš„æ½œåœ¨è”åˆæ²»ç–—é¶ç‚¹</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&amp;mid=2247790821&amp;idx=2&amp;sn=5a2a37ffe0da89b24e2252f4b7ca23c6">Cell Stem Cellï¼šé€†è½¬æº¶é…¶ä½“åŠŸèƒ½éšœç¢ï¼Œè®©è¡°è€é€ è¡€å¹²ç»†èƒæ¢å¤å¹´è½»æ€</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2OTU2MzM2NA==&amp;mid=2247493044&amp;idx=1&amp;sn=66969bddc7b4240a5fd0b5f88486bf17">åˆšåˆšå‘è¡¨çš„7.5åˆ†ç”Ÿä¿¡ï¼Œä¸€ç§ç”¨äºç²¾å‡†æ³›ç™Œåˆ†ç±»çš„å¤šè¡¨å¾æ·±åº¦å­¦ä¹ æ¡†æ¶ï¼åªè¦æœ‰æŠ€æœ¯ï¼Œè¿˜åšä»€ä¹ˆå®éªŒï¼</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzYyNDMwNjg3Nw==&amp;mid=2247484117&amp;idx=1&amp;sn=391bedbf530054bf63cfb4dfa9aabfc6">æ·‹å·´å¾ªç¯ï¼ˆå»ºè®®æ”¶è—ï¼‰</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247569157&amp;idx=2&amp;sn=b9322143614e453c9f349cb66115fb2e">ä»å¿ƒæ¢—åˆ°å…¨èº«ç‚ç—‡ï¼Œéƒ½æŒ‡å‘åŒä¸€å…³é”®è›‹ç™½ï¼é¶å‘è¯ç‰©æœ‰æœ›æ”¹å†™æ²»ç–—æ ¼å±€</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzU0ODQyNjQxOA==&amp;mid=2247555219&amp;idx=2&amp;sn=fd9a3eb054b683b9582983f92008c644">Sci Tra Med | å®éªŒæ€§èƒ¶è´¨æ¯ç»†èƒç˜¤è¯•éªŒç»“æœæœ‰æœ›æ¨åŠ¨æ‚£è€…ç›‘æµ‹ä¸ç–—æ³•çš„é©æ–°</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzU0ODQyNjQxOA==&amp;mid=2247555219&amp;idx=1&amp;sn=ec9f0298a517f2f715dcc8a4b14c62ad">Nat Biotech | æœ€æ–°è‚¿ç˜¤èŠ¯ç‰‡æŠ€æœ¯ï¼šåŠ©åŠ›å®ä½“ç˜¤CAR-Tç–—æ³•ç ”å‘</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2OTczNjI0OQ==&amp;mid=2247529067&amp;idx=1&amp;sn=3b2ce9fe982f69c25d756186fcc17ae3">å“ªå®¶å…¬å¸èƒ½è£ç™»é«˜å¼•ç»†èƒå› å­å›½äº§ç¬¬ä¸€ï¼Ÿ</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2NTE1MzU4NQ==&amp;mid=2247523470&amp;idx=1&amp;sn=eaa08e109ddfa60c5cf96e3bfcfb9bc6">ä¸­å›½ç§‘å­¦é™¢åŒ—äº¬åŸºå› ç»„ç ”ç©¶æ‰€éƒäºšé™å›¢é˜Ÿè¯šæ‹›ç‰¹åˆ«ç ”ç©¶åŠ©ç†ï¼ˆåšå£«åï¼‰</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248818&amp;idx=7&amp;sn=8969a46e4815ff49bb16b476c894b644">Natureï¼šscWGS+scRNAè§£å¯†å…¨åŸºå› ç»„å€å¢çš„æ¼”åŒ–åŠ¨æ€</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248818&amp;idx=4&amp;sn=d6e97f1b3e8a7d29b6ccd973803e3b36">åˆ«å‚»äº†ï¼å¤šç»„å­¦åªåšå…³è”å’Œé€šè·¯ï¼Ÿè¿™æ³¢è¡€äºï¼</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248818&amp;idx=2&amp;sn=1eb33102d6f16b04517c0d956730aef4">è…¾è®¯ç™»26.6åˆ†Natureå­åˆŠï¼Œåªæœ‰ä½ æƒ³ä¸åˆ°çš„è›‹ç™½è´¨ï¼æ²¡æœ‰è¿™ä¸ªæ¨¡å‹é¢„æµ‹ä¸äº†çš„</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzU5MDcwNzg0MA==&amp;mid=2247659415&amp;idx=2&amp;sn=67bb782fa7826cdeab4f004af7f64e6e">æœºä½“ç¨³æ€çš„å…ç–«è°ƒèŠ‚â€”â€”è‹å†°æ•™æˆä¸Immunityå¯¹è¯å½• | Cell Symposiaæ‘˜è¦å¾é›†ä¸­</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247650773&amp;idx=2&amp;sn=7075a84eec2b46ec4cf1ea4d75bcda95">ä¸ºçœç»è´¹ï¼Œå¯¼å¸ˆå–Šå¤§å®¶æ‰‹æ“æŠ—ä½“ï¼Ÿä½†æˆ‘ä¸¤ä¸ªæœˆéƒ½æ²¡æ‹¿åˆ°é˜³æ€§å…‹éš†</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247650773&amp;idx=1&amp;sn=1045376fce5df2679b210024ef1e2bbd">æˆåŠŸé€†è½¬è€å¹´ç—´å‘†ï¼å››å·å¤§å­¦åè¥¿åŒ»é™¢å‘ç°ï¼šæ³¨å°„ 2 å°æ—¶ï¼Œæ¸…é™¤è¿‘ 50% å¤§è„‘ã€Œåƒåœ¾ã€ï¼Œè®°å¿†æ¢å¤æŒç»­åŠå¹´</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656510953&amp;idx=1&amp;sn=bde7ad9bca478cda3596cf4b2821dfba">ä¸´åºŠè¯•éªŒç»“æœå‘å¸ƒï¼åŒ—äº¬åå’ŒåŒ»é™¢æ›¾å°å³°å›¢é˜Ÿé¢†è¡”æ–°å‹æŠ—CD38å•å…‹éš†æŠ—ä½“åœ¨ç³»ç»Ÿæ€§çº¢æ–‘ç‹¼ç–®æ²»ç–—ä¸­è¡¨ç°å‡ºè‰¯å¥½å®‰å…¨æ€§å’Œæ˜¾ç€ç–—æ•ˆ</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5NjgxNjkwOA==&amp;mid=2247503146&amp;idx=2&amp;sn=0a9523fcf992b9580c2d83231dc0a223">è„‘ç§‘å­¦ | Nature | å…¨çš®å±‚åŸä½æµ‹åºæ­ç¤ºè¾“å…¥ä¾èµ–çš„åŒºåŸŸèº«ä»½</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5NjgxNjkwOA==&amp;mid=2247503146&amp;idx=1&amp;sn=198def38ad29902f15ac1b4332071f5e">ç»¼è¿° | Brief.Bioinform. | ç»†èƒé—´é€šä¿¡æ¨æ–­çš„ç ”ç©¶è¿›å±•ä¸æŒ‘æˆ˜ï¼šå·¥å…·ã€èµ„æºåŠæœªæ¥æ–¹å‘çš„å…¨é¢ç»¼è¿°</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&amp;mid=2247790821&amp;idx=4&amp;sn=245af9481df2918b06674f76e5ef535f">Nature Neuroscienceï¼šææ˜/è‚–æ½‡/æœ±å³°/æ–¹è´»å„’åˆä½œæ­ç¤ºåŒç›¸æƒ…æ„Ÿéšœç¢é—ä¼ ç‰¹å¾å’Œç»†èƒæœºåˆ¶</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzkxODY4NDEwMA==&amp;mid=2247490106&amp;idx=1&amp;sn=7278c3bc770a69e7f2ec7ba04f975d7a">çº¿ç²’ä½“è‡ªå™¬</a></li></ul></div></details><details><summary><a name=æ›´å¤š-æ•°æ®å‰æ²¿></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (34æ¡)</summary><div class=details-content markdown=1><ul><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289249">GSE289249 å¤šæ¢³æŠ‘åˆ¶å¤åˆç‰© 2 ä¸ DNA ç”²åŸºåŒ–ä¹‹é—´çš„ä¸²æ‰°ä»‹å¯¼ç¥ç»å†…åˆ†æ³Œå‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§ [RRBS]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287164">GSE287164 ISG20 ç¼ºå¤±å¯¹ EMT6 å°é¼ ä¹³è…ºç™Œç»†èƒåŸºå› è¡¨è¾¾çš„å½±å“ï¼ˆRNA-Seqï¼‰ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286954">GSE286954 å‰åˆ—è…ºè…ºç™Œå’Œç¥ç»å†…åˆ†æ³Œå‰åˆ—è…ºç™Œæ¨¡å‹çš„è¡¨è§‚é—ä¼ å­¦åˆ†æï¼Œä»¥äº†è§£DNMT-EZH2çš„ç›¸äº’ä½œç”¨ã€‚[Cut&amp;Run]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE273769">GSE273769 PLK1 æŠ‘åˆ¶å‰‚ Onvansertib ä¸ FOLFIRI å’Œ Bevacizumab è”åˆç”¨äº KRAS çªå˜è½¬ç§»æ€§ç»“ç›´è‚ ç™Œçš„äºŒçº¿æ²»ç–—ï¼šä¸€é¡¹å•è‡‚ II æœŸè¯•éªŒã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266604">GSE266604 å…ˆå…†å­ç—«èƒç›˜ç»„ç»‡çš„ç©ºé—´è½¬å½•ç»„åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE251960">GSE251960 Beckwith-Wiedemann ç»¼åˆå¾å’Œå¤§åä»£ç»¼åˆå¾æ¶‰åŠç”²åŸºåŒ–ç»„ã€è½¬å½•ç»„å’ŒæŸ“è‰²è´¨æ„å‹çš„æ”¹å˜ [RNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310509">GSE310509 SREBPä¿¡å·é€šè·¯è°ƒèŠ‚è‚ºéƒ¨é©»ç•™è®°å¿†Bç»†èƒä»£è°¢ä»¥ç»´æŒè¿‡æ•è®°å¿†</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311170">GSE311170 CDK12 å’Œ BAF æŠ‘åˆ¶å‰‚è”åˆä½¿ç”¨å¯ååŒæŠ‘åˆ¶ä¸‰é˜´æ€§ä¹³è…ºç™Œç»†èƒç³»çš„å­˜æ´»ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311157">GSE311157 åŒºåŸŸå‡è¡¡åŒ–å½’ä¸€åŒ–ä»¥æ”¹å–„è¡¨è§‚é—ä¼ ä¿¡å·çš„å¯¹é½</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300112">GSE300112 å®«é¢ˆé˜´é“å¾®ç”Ÿç‰©ç»„ä¸äººç±»å®«é¢ˆå¤–ä¸Šçš®å’Œé»è†œä¸‹å±‚ä¸­ç©ºé—´å—é™çš„å®¿ä¸»è½¬å½•ç‰¹å¾ç›¸å…³</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297099">GSE297099 æ¢å¤æœºæ¢°è¡¨å‹å¯é€†è½¬å¯Œå«ç»†èƒå¤–åŸºè´¨çš„å£°å¸¦ç™Œçš„æ¶æ€§ç‰¹å¾</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289681">GSE289681 æ‹Ÿå—èŠ¥èŠ±å‘è‚²æ—©æœŸé˜¶æ®µèŠ±è¯±å¯¼ç³»ç»Ÿ (FIS) ä¸­ leunig_homolog (luh) å’Œ leunig (lug) çªå˜ä½“çš„è½¬å½•ç»„åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278894">GSE278894 Sox9f/f å’Œ Sox9HKO å°é¼ åŸä»£è‚ç»†èƒè½¬å½•ç»„çš„ RNA-seq åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310962">GSE310962 EGFRçªå˜å‹å°ç»†èƒè‚ºç™Œå­˜åœ¨è‚¿ç˜¤å†…å¼‚è´¨æ€§ï¼Œå¯é€šè¿‡MEKæŠ‘åˆ¶å‰‚è”åˆç–—æ³•è¿›è¡Œé¶å‘æ²»ç–—ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296748">GSE296748 Dp16 è‚è„è½¬å½•ç»„</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296500">GSE296500 Crnicç ”ç©¶æ‰€äººç±»ä¸‰ä½“è®¡åˆ’ - 21ä¸‰ä½“æ¨¡å‹å›¾è°±ï¼šæ¥è‡ªæˆå¹´é‡ç”Ÿå‹å’ŒDp16å°é¼ è‚è„ç»„ç»‡ï¼ˆÂ±é«˜è„‚é¥®é£Ÿï¼‰çš„PolyA RNAæµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296449">GSE296449 Crnicç ”ç©¶æ‰€äººç±»ä¸‰ä½“è®¡åˆ’ - 21ä¸‰ä½“æ¨¡å‹å›¾è°±ï¼šæ¥è‡ªäººç±»iPSCè¡ç”Ÿè‚ç»†èƒæ ·ç»†èƒçš„PolyA RNAæµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296420">GSE296420 Crnicç ”ç©¶æ‰€äººç±»ä¸‰ä½“è®¡åˆ’ - 21ä¸‰ä½“æ¨¡å‹å›¾è°±ï¼šæ¥è‡ªæˆå¹´é‡ç”Ÿå‹å’ŒDp16å°é¼ è‚è„ç»„ç»‡çš„PolyA RNAæµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295901">GSE295901 EBF1 å’Œ PAX5 å¯¹ T ç»†èƒè°±ç³»æ½œèƒ½å‘æŒ¥å‰‚é‡ä¾èµ–æ€§çš„è¡¨è§‚é—ä¼ æŠ‘åˆ¶ä½œç”¨ [ChIPmentation]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295899">GSE295899 EBF1 å’Œ PAX5 å¯¹ T ç»†èƒè°±ç³»æ½œèƒ½å‘æŒ¥å‰‚é‡ä¾èµ–æ€§çš„è¡¨è§‚é—ä¼ æŠ‘åˆ¶ä½œç”¨ [scMultiome]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE195997">GSE195997 HIFæŠ‘åˆ¶å‰‚32-134Dè”åˆæŠ—PD-1ç–—æ³•å¯é˜»æ–­å°é¼ è‚ç»†èƒç™Œç”Ÿé•¿å¹¶æ ¹é™¤è‚¿ç˜¤</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311367">GSE311367 å¯¹è¡¨è¾¾é‡ç”Ÿå‹ RUNX1 å’ŒåµŒåˆè›‹ç™½ RUNX11-299-SPI11-102 çš„ 293T ç»†èƒè¿›è¡Œ DNA ç”²åŸºåŒ–åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303684">GSE303684 YAP1åŠŸèƒ½éšœç¢ä¿ƒè¿›ä¸ä¹³è…ºç™Œæ˜“æ„Ÿæ€§ç›¸å…³çš„åˆ†å­ç‰¹æ€§</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE251961">GSE251961 Beckwith-Wiedemannç»¼åˆå¾å’Œå¤§åä»£ç»¼åˆå¾æ¶‰åŠç”²åŸºåŒ–ç»„ã€è½¬å½•ç»„å’ŒæŸ“è‰²è´¨æ„è±¡çš„æ”¹å˜</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE251959">GSE251959 Beckwith-Wiedemann ç»¼åˆå¾å’Œå¤§åä»£ç»¼åˆå¾æ¶‰åŠç”²åŸºåŒ–ç»„ã€è½¬å½•ç»„å’ŒæŸ“è‰²è´¨æ„å‹çš„æ”¹å˜ [WGBS]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311458">GSE311458 ä¸€é¡¹è¯„ä¼°è¥¿è¾¾ç±³å¾·è”åˆç»´å¥ˆæ‰˜å…‹ã€é˜¿æ‰èƒè‹·ã€é˜¿å…‹æ‹‰éœ‰ç´ ã€é˜¿ç³–èƒè‹·å’Œç²’ç»†èƒé›†è½åˆºæ¿€å› å­æ²»ç–—éš¾æ²»æ€§/å¤å‘æ€§æ€¥æ€§é«“ç³»ç™½è¡€ç—…çš„ I æœŸç ”ç©¶ï¼šä¸´åºŠå®‰å…¨æ€§ã€æœ‰æ•ˆæ€§å’Œç›¸å…³æ€§åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311175">GSE311175 å•ç»†èƒå¤šç»„å­¦åˆ†ææ­ç¤º CTCF æ˜¯è‚ºå½¢æ€å‘ç”Ÿå’Œç¥–ç»†èƒç»´æŒçš„å…³é”®è°ƒæ§å› å­ I</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311050">GSE311050 æŠ—ä½“å¤šæ ·æ€§äº§ç”Ÿçš„æŸ“è‰²è´¨æŠ˜å åŸç†</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306856">GSE306856 Venetoclax é€šè¿‡è„‚è‚ªé…¸æ°§åŒ–å¢å¼ºå¤å‘æ€§æ€¥æ€§é«“ç³»ç™½è¡€ç—…ä¸­ Î³Î´T ç»†èƒçš„æŠ—ç™½è¡€ç—…æ´»æ€§ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283418">GSE283418 æä»æ ¸ç¥ç»å…ƒçš„ç©ºé—´åˆ†å­è°±åˆ†æå®ç°äº†é’ˆå¯¹ç–¼ç—›ä¸é€‚çš„ç²¾å‡†è¯ç†å­¦æ²»ç–—</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283060">GSE283060 äººæºåŒ–å•é…°ç”˜æ²¹é…°åŸºè½¬ç§»é…¶ 2 å°é¼ åœ¨å–‚é£Ÿé«˜è„‚é¥®é£Ÿåä¼šå˜å¾—è‚¥èƒ–å¹¶å‘å±•ä¸ºä»£è°¢åŠŸèƒ½éšœç¢ç›¸å…³çš„è„‚è‚ªè‚ç–¾ç—…</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282984">GSE282984 åŸºäºç½‘ç»œè¯ç†å­¦å’Œè½¬å½•ç»„å­¦æ¢ç´¢èŠ¥é…¸çš„æŠ—æµæ„Ÿæœºåˆ¶</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282864">GSE282864 é˜»å¡æ€§ç¡çœ å‘¼å¸æš‚åœæ‚£è€…è¡€æµ†å¤–æ³Œä½“microRNAçš„å·®å¼‚è¡¨è¾¾è°±</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270116">GSE270116 æ·‹å·´æ¯’ç´ Î±æ˜¯æ€¥æ€§é«“ç³»ç™½è¡€ç—…çš„å†…æºæ€§æŠ‘åˆ¶å› å­</a></li></ul></div></details><hr><p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-26 21:34</em><br><em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p></div><footer class=post__footer><div class="post__tags tags clearfix"><svg class="tags__badge icon icon-tag" width="16" height="16" viewBox="0 0 32 32"><path d="M4 0h8s2 0 4 2l15 15s2 2 0 4L21 31s-2 2-4 0L2 16s-2-2-2-4V3s0-3 4-3m3 10a3 3 0 000-6 3 3 0 000 6"/></svg><ul class=tags__list><li class=tags__item><a class="tags__link btn" href=../../../tags/research/ rel=tag>Research</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/daily/ rel=tag>Daily</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/week482025/ rel=tag>Week482025</a></li></ul></div></footer></article></main><div class="authorbox clearfix"><div class=authorbox__header><span class=authorbox__name>About Bloger</span></div></div><nav class="pager flex"><div class="pager__item pager__item--prev"><a class=pager__link href=../../../posts/dailyreports/2025-11-26/ rel=prev><span class=pager__subtitle>Â«&#8201;Previous</span><p class=pager__title>ç§‘ç ”æ—¥æŠ¥ 2025-11-26</p></a></div><div class="pager__item pager__item--next"><a class=pager__link href=../../../posts/dailyreports/2025-11-28/ rel=next><span class=pager__subtitle>Next&#8201;Â»</span><p class=pager__title>ç§‘ç ”æ—¥æŠ¥ 2025-11-28</p></a></div></nav><section class=comments><div id=disqus_thread></div><script>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//kkitown.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></section></div><aside class=sidebar><div class="widget-search widget"><form class=widget-search__form role=search method=get action=https://google.com/search><input class=widget-search__field type=search placeholder=Searchâ€¦ name=q aria-label=Searchâ€¦>
<input class=widget-search__submit type=submit value=Search>
<input type=hidden name=sitesearch value=https://ixxmu.github.io/></form></div><div class="widget-recent widget"><h4 class=widget__title>Recent Posts</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2025-12-04/>ç§‘ç ”æ—¥æŠ¥ 2025-12-04</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2025-12-03/>ç§‘ç ”æ—¥æŠ¥ 2025-12-03</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2025-12-02/>ç§‘ç ”æ—¥æŠ¥ 2025-12-02</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2025-12-01/>ç§‘ç ”æ—¥æŠ¥ 2025-12-01</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2025-11-30/>ç§‘ç ”æ—¥æŠ¥ 2025-11-30</a></li></ul></div></div><div class="widget-categories widget"><h4 class=widget__title>Categories</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../categories/dailyreport/>DailyReport</a></li><li class=widget__item><a class=widget__link href=../../../categories/learnr/>LearnR</a></li></ul></div></div><div class="widget-taglist widget"><h4 class=widget__title>Tags</h4><div class=widget__content><a class="widget-taglist__link widget__link btn" href=../../../tags/daily/ title=Daily>Daily (36)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/research/ title=Research>Research (36)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week452025/ title=Week452025>Week452025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week462025/ title=Week462025>Week462025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week472025/ title=Week472025>Week472025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week482025/ title=Week482025>Week482025 (7)</a></div><a href=../../../tags/></a></div><div class="widget-social widget"><h4 class="widget-social__title widget__title">Social</h4><div class="widget-social__content widget__content"><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Facebook rel="noopener noreferrer" href=https://facebook.com/username target=_blank><svg class="widget-social__link-icon icon icon-facebook" width="24" height="24" viewBox="0 0 352 352"><path d="m0 32v288c0 17.5 14.5 32 32 32h288c17.5.0 32-14.5 32-32V32c0-17.5-14.5-32-32-32H32C14.5.0.0 14.5.0 32zm320 0v288h-83V212h41.5l6-48H237v-31c0-14 3.5-23.5 23.5-23.5h26V66c-4.4-.6-19.8-1.5-37.5-1.5-36.9.0-62 22.2-62 63.5v36h-42v48h42v108H32V32z"/></svg>
<span>Facebook</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Twitter rel="noopener noreferrer" href=https://twitter.com/username target=_blank><svg class="widget-social__link-icon icon icon-twitter" width="24" height="24" viewBox="0 0 384 312"><path d="m384 36.9c-14.1 6.3-29.3 10.5-45.2 12.4 16.3-9.7 28.8-25.2 34.6-43.6-15.2 9-32.1 15.6-50 19.1-14.4-15.2-34.9-24.8-57.5-24.8-43.5.0-78.8 35.3-78.8 78.8.0 6.2.7 12.2 2 17.9-65.5-3.3-123.5-34.6-162.4-82.3C20 26 16.1 39.6 16.1 54c0 27.3 13.9 51.4 35 65.6-12.9-.4-25.1-4-35.7-9.9v1c0 38.2 27.2 70 63.2 77.2-6.6 1.8-13.6 2.8-20.8 2.8-5.1.0-10-.5-14.8-1.4 10 31.3 39.1 54.1 73.6 54.7-27 21.1-60.9 33.7-97.8 33.7-6.4.0-12.6-.4-18.8-1.1C34.9 299 76.3 312 120.8 312c144.9.0 224.1-120 224.1-224.1.0-3.4-.1-6.8-.2-10.2 15.4-11.1 28.7-25 39.3-40.8z"/></svg>
<span>Twitter</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Instagram rel="noopener noreferrer" href=https://www.instagram.com/username target=_blank><svg class="widget-social__link-icon icon icon-instagram" width="24" height="24" viewBox="0 0 256 256"><circle cx="193" cy="59" r="15"/><path fill-rule="evenodd" d="M101 0h54c41 0 58.4 3.9 74.5 17C256.2 37.5 256 74.8 256 97.7v60c0 26.7.0 60.4-26.5 81.4-16 13.4-33.5 16.9-74.5 16.9h-54c-41 0-57.5-3.5-74.5-16.9C1 218.9.5 186.3.1 160.5L0 155V97.7c0-23-.2-60.2 26.5-80.7C45 2 60 0 101 0zm4.9 23h44.3c45.8.0 58.3 3.5 70.3 17.5 11.8 13.2 12 30.1 12.5 62.9V156c.2 20.8.3 45.8-12.5 59.5-12 14-24.5 17.5-70.3 17.5h-44.3c-45.9.0-57.3-3.5-70.4-17.5-12.2-13-12.3-36.5-12.4-56.7v-55.6c.4-32.6.7-49.6 12.4-62.7C48 26.5 60 23 105.9 23zm19.6 144.5a42 42 0 100-84 42 42 0 000 84zm0 22.5a64.5 64.5.0 100-129 64.5 64.5.0 000 129z"/></svg>
<span>Instagram</span></a></div></div></div></aside></div><footer class=footer><div class="container footer__container flex"><div class=footer__copyright>&copy; 2025 ç”Ÿä¿¡æ™®æ‹‰æ–¯.
<span class=footer__copyright-credits>Generated with <a href=https://gohugo.io/ rel="nofollow noopener" target=_blank>Hugo</a> and <a href=https://github.com/Vimux/Mainroad/ rel="nofollow noopener" target=_blank>Mainroad</a> theme.</span></div></div></footer></div><script async defer src=../../../js/menu.js></script><script src=../../../js/custom.js></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.6/MathJax.js?config=TeX-AMS-MML_HTMLorMML" async></script></body></html>